Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to boost survival in elderly lung cancer patients

NCT ID NCT06656598

Disease control Sponsor: Intergroupe Francophone de Cancerologie Thoracique Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This study tests whether giving immunotherapy (Cemiplimab) along with chemotherapy (Carboplatin and Paclitaxel) before radiation can help elderly or unfit patients with stage III non-small cell lung cancer live longer without their cancer getting worse. The trial will enroll 152 participants and compare this approach to standard care. The goal is to improve survival while keeping side effects manageable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Carboplatin, Paclitaxel, Cemiplimab (Libtayo), and hypofractionated radiotherapy
What this could lead to
If successful, this could offer a more effective treatment option for elderly or unfit patients with stage III lung cancer, potentially improving survival without the need for more aggressive therapy.
What could go wrong
This is an early Phase 2 trial with only 152 participants, so results may not apply to all patients. The combination of drugs and radiation may cause side effects like fatigue, low blood counts, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 152 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jan 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients must have signed and dated an IRB/IEC approved written informed consent form in accordance with regulatory and institutional guidelines. This must be obtained before the performance of any protocol related procedures that are not part of normal subject care. 2. Patients must be willing and able to comply with scheduled visits, treatment schedule, and laboratory testing. 3. Age ≥ 18 years. 4. Histologically or cytologically confirmed locally advanced non small cell lung cancer (NSCLC) stage IIIA non resectable, IIIB or IIIC accordingly to 8th classification TNM, UICC 2015. 5. Unfit or elderly patients as defined below: * ≥ 70 years , PS 0 to 1, charlson comorbidity criterion : all score * \< 70 years , PS 0 to 1, charlson comorbidity criterion : score ≥ 3 * \< 70 years , PS , charlson comorbidity criterion : all score 6. Patients eligible for treatment with sequential radio-chemotherapy validated by multidisciplinary committee. 7. Measurable disease according to RECIST 1.1 per investigator assessment. The radiological assessment has to be done within the timelines indicated. 8. Respiratory function: * FEV1 ≥ 40% of theoretical value, * DLCO ≥ 40%. 9. Bone marrow function: * absolute neutrophil count (ANC) ≥ 1.5.109/L, * platelets ≥ 100.109/L, * hemoglobin ≥ 9 g/dl. 10. Renal and hepatic function: * estimated creatinine clearance ≥ 45 ml/min, * bilirubin ≤1.5xULN, * AST ALT ≤3xULN, * Albumin ≥28g/dl. 11. Participant has national health insurance coverage. 12. Effective method of contraception during the treatment and during the 6 months following the last dose for patients of childbearing potential and for male subjects who are sexually active with a woman of childbearing potential. 13. Expression of PD-L1 as assessed locally by the investigator center. Exclusion Criteria: 1. Immunotherapy or chemotherapy contra-indicated. 2. Patients eligible for treatment with concomitant radio-chemotherapy validated by multidisciplinary committee. 3. Stage I or II NSCLC. 4. Previously received a treatment with anti-PD1/PDL1, anti-CTLA, or other antineoplastic immunotherapy or chemotherapy for NSCLC. 5. Histology other than primary non-small cell lung cancer. 6. Known activating EGFR mutation or ALK or ROS1 translocation. 7. Metastatic NSCLC including brain metastasis. 8. Patients not eligible for curative radiotherapy (tumor extension, predictable dose constraints that cannot be met). 9. Severe uncontrolled comorbidities or severe intercurrent disease: acute coronary syndrome less than 3 months old, unstable angina, heart failure with LVEF ≤30%, uncontrolled hypertension, Child B or C cirrhosis, severe sepsis, myocarditis or any other active conditions that would contraindicate chemotherapy, immunotherapy, or radiotherapy in the opinion of the investigator. 10. Weight loss ≥15% of total body weight in the last 6 months. 11. ECOG PS upper 2 12. Active autoimmune pathology. History of autoimmune pathology including myasthenia, Guillain-Barre syndrome, lupus erythematosus, antiphospholipid syndrome, Wegener's granulomatosis, glomerulonephritis, inflammatory bowel disease, vasculitis, sarcoidosis, uveitis. Autoimmune thyroid pathologies under replacement therapy as well as type 1 diabetes under insulin are authorized. 13. History of idiopathic pulmonary fibrosis, organized pneumopathy or signs of active interstitial pulmonary pathology on CT scan. 14. Any immunosuppressive therapy received within 28 days and corticosteroids \> 10mg/day of prednisone or equivalent received within 7 days prior the start of chemotherapy excepted hydrocortisone replacement for adrenal insufficiency or pituitary disease not considered immunosuppressive therapy. 15. Chronic active infection including tuberculosis, HIV, hepatitis B (HBsAg positive) or C. Patients with a history of cured hepatitis B (anti HBc and absence of negative HBs antigen) are eligible. In case of hepatitis C (anti HCV Ac) patients are eligible if the HCV PCR is negative. 16. Severe infections (including covid-19 infection) within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia. 17. History of neoplastic disease (other than NSCLC) less than 3 years old or progressive (except basal cell carcinoma of the skin and carcinoma in situ of the cervix). 18. History of thoracic radiotherapy. 19. Live attenuated vaccine received within 28 days of starting chemotherapy 20. History of organ or bone marrow transplantation. 21. Major surgery within 4 weeks of starting treatment. 22. Patient already included in another therapeutic trial. 23. Positive pregnancy test or breastfeeding woman. 24. Protected adults (under guardianship or curatorship). 25. Inability to undergo medical monitoring of the study (for geographical, social and/or physical reasons). 26. Patients unable to understand the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage III NSCLC are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stage III NSCLC

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    25 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Angers - CHU

    RECRUITING

    Angers, France

    Contact Email: •••••@•••••

  • Angers - Centre Paul Papin

    RECRUITING

    Angers, France

    Contact Email: •••••@•••••

  • Avignon - CH

    RECRUITING

    Avignon, France

    Contact Email: •••••@•••••

  • Bordeaux - CHU

    RECRUITING

    Pessac, France

    Contact Email: •••••@•••••

  • Boulogne - Ambroise Paré

    RECRUITING

    Boulogne, France

    Contact Email: •••••@•••••

  • Brest - CHU

    RECRUITING

    Brest, France

    Contact Email: •••••@•••••

  • Caen - CHU

    RECRUITING

    Caen, France

    Contact Email: •••••@•••••

  • Caen - CRLCC

    RECRUITING

    Caen, France

    Contact Email: •••••@•••••

  • Créteil - CHI

    RECRUITING

    Créteil, France

    Contact Email: •••••@•••••

  • Dijon - CRLCC

    RECRUITING

    Dijon, France

    Contact Email: •••••@•••••

  • Le Mans - CHG

    RECRUITING

    Le Mans, France

    Contact Email: •••••@•••••

  • Lille - CRLCC

    RECRUITING

    Lille, France

    Contact Email: •••••@•••••

  • Lyon - HCL

    RECRUITING

    Pierre-Bénite, France

    Contact Email: •••••@•••••

  • Marseille - APHM

    RECRUITING

    Marseille, France

    Contact Email: •••••@•••••

  • Mulhouse - GHRMSA

    RECRUITING

    Mulhouse, France

    Contact Email: •••••@•••••

  • Nantes - CRLCC

    RECRUITING

    Saint-Herblain, France

    Contact Email: •••••@•••••

  • Paris - Bichat

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Paris - Hôpital Cochin

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Paris - Tenon

    RECRUITING

    Paris, France

    Contact Email: •••••@•••••

  • Rennes - CHU

    RECRUITING

    Rennes, France

    Contact Email: •••••@•••••

  • Rouen - Centre Henri Becquerel

    RECRUITING

    Rouen, France

    Contact Email: •••••@•••••

  • Strasbourg - CRLCC

    RECRUITING

    Strasbourg, France

    Contact Email: •••••@•••••

  • Toulouse - CHU

    RECRUITING

    Toulouse, France

    Contact Email: •••••@•••••

  • Tours - CHU

    RECRUITING

    Tours, France

    Contact Email: •••••@•••••

  • Vandoeuvre-lès-Nancy - CRLCC

    RECRUITING

    Vandœuvre-lès-Nancy, France

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.